CDXSMEDIUM SIGNALFINANCIAL10-K

CDXS showed strong revenue growth of 32% and significantly improved cash position, but continues burning cash with declining equity and rising debt levels.

The company demonstrates positive operational momentum with revenue acceleration and meaningful improvements in operating losses and cash burn rates. However, the declining stockholders' equity combined with increased debt suggests ongoing financing pressures despite the improved cash position, likely from equity raises or asset sales.

Comparing 2026-03-11 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

CDXS delivered strong top-line growth with revenue increasing 32% to $138.6M while substantially improving operating performance, cutting losses by 29-33% across key metrics and reducing cash burn by 61%. The balance sheet shows mixed signals with cash more than doubling to $50.8M (likely from financing activities) but stockholders' equity declining 25% and total debt rising 39%, indicating the company is still navigating capital structure challenges despite operational improvements. The dramatic 69% drop in accounts receivable alongside revenue growth suggests either collection timing issues or changes in customer mix/terms.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+163.7%
$19.3M$50.8M

Cash position surged 163.7% — strong cash generation or capital raise providing significant financial cushion.

Accounts Receivable
Balance Sheet
-68.5%
$31.9M$10.0M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Operating Cash Flow
Cash Flow
+60.8%
-$49.4M-$19.4M

Operating cash flow surged 60.8% — exceptional cash generation, highest quality earnings signal.

Total Debt
Balance Sheet
+38.7%
$28.9M$40.1M

Debt increased 38.7% — substantial leverage increase; assess whether deployed for growth or covering losses.

Net Income
P&L
+32.6%
-$65.3M-$44.0M

Net income grew 32.6% — bottom-line growth signals improving overall business health.

Revenue
P&L
+32.3%
$104.8M$138.6M

Strong top-line growth of 32.3% — accelerating demand or successful expansion into new markets.

Operating Income
P&L
+28.7%
-$58.5M-$41.7M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Stockholders Equity
Balance Sheet
-24.5%
$66.9M$50.5M

Equity decreased 24.5% — buybacks or losses reducing book value, monitor solvency ratios.

Total Liabilities
Balance Sheet
+18.5%
$82.1M$97.3M

Liabilities increased 18.5% — monitor debt-to-equity ratio and interest coverage.

SG&A Expense
P&L
-14.6%
$55.1M$47.1M

SG&A reduced 14.6% — improved cost efficiency or headcount reduction improving operating margins.

LANGUAGE CHANGES
NEW — 2026-03-11
PRIOR — 2025-02-27
ADDED
As of March 5, 2026, there were 90,869,349 shares of the registrant s Common Stock, par value $0.0001 per share, outstanding.
SUMMARY RISK FACTORS Our business is subject to numerous risks and uncertainties, including those described in Part I, Item 1A: Risk Factors in this Annual Report on Form 10-K.
You should carefully consider these risks and uncertainties when investing in our common stock.
The principal risks and uncertainties affecting our business include the following: We have a history of net losses and we may not achieve or maintain profitability.
Failure to validate performance at scale, demonstrate regulatory acceptance, or overcome other challenges with the new technologies could impede customer adoption and our revenues.
+7 more — sign up free →
REMOVED
As of February 24, 2025, there we re 82,837,311 shares of the registrant s Common Stock, par value $0.0001 per share, outstanding.
BUSINESS COMPANY OVERVIEW We are a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, and we leverage o ur proprietary CodeEvolver directed evolution technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins.
Enzymes are naturally occurring biological molecules critical to almost all biochemical reactions that sustain life.
We focus on leveraging our technology and capacity to enhance the properties and performance of enzymes to drive pivotal improvements in manufacturing of complex therapeutics across two key focus areas: our foundational, revenue-generating pharma biocatalysis business and our Enzyme-Catalyzed Oligonucleotide Synthesis ( ECO Synthesis ) manufacturing platform, which is comprised of enzymatic tools, and processes, designed to enable large-scale manufacture of RNA interference ( RNAi ) therapeutics.
In July 2023, we announced that we discontinued investment in certain development programs, primarily in our novel biotherapeutics business segment.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →